Serum endocan level and diastolic functions in the case of lead exposure
Serum endocan level and diastolic functions in the case of lead exposure
Background/aim: Lead can cause morphological and functional changes in heart, and inflammation and endothelial dysfunction invasculature. Endocan, as a novel indicator of endothelial dysfunction, has been used for cardiovascular diseases. This study investigatedthe relationship between lead exposure, endocan levels, and diastolic functions.Materials and methods: A total of 51 lead-exposed workers without a known cardiovascular disease or risk factors and 54 healthycontrols were enrolled. All participants underwent transthoracic echocardiography. Blood lead and serum endocan levels were analyzed.Results: Baseline demographic and clinical characteristics were found to be similar between groups. Median blood lead (32 vs 1.5 µg/dL,P < 0.001) and serum endocan levels (67 vs 57.1 pg/mL, P = 0.02) were significantly higher in the lead-exposed group. Serum endocanlevel showed a positive correlation with blood lead levels (r = 0.404, P = 0.003) in lead-exposed workers. Serum endocan level was anindependent risk factor for increased E/E’ ratio (β = 0.704, P = 0.002) and left atrial volume index (β = 1.158, P = 0.011) and higher levelof lead in blood was an independent risk factor for increased E wave (β = 8.004, P = 0.022) in lead-exposed workers.Conclusion: Worsened diastolic functions may be seen in the course of lead exposure. Due to sharing a similar mechanism, a higherserum level of endocan may be a valuable laboratory clue for impaired diastolic function in this population.
___
- 1. Jain NB, Potula V, Schwartz J, Vokonas PS, Sparrow D, Wright
RO, Nie H, Hu H. Lead levels and ischemic heart disease in
a prospective study of middle-aged and elderly men: the VA
Normative Aging Study. Environ Health Perspect 2007; 115:
871-875.
- 2. Gambelunghe A, Sallsten G, Borne Y, Forsgard N, Hedblad
B, Nilsson P, Fagerberg B, Engstrom G, Barregard L. Lowlevel exposure to lead, blood pressure, and hypertension in a
population-based cohort. Environ Res 2016; 149: 157-163.
- 3. Poreba R, Gac P, Poreba M, Mazur G. Echocardiographic
assessment of myocardial function in workers occupationally
exposed to lead without clinically evident heart disease.
Environ Toxicol Pharmacol 2013; 36: 522-528.
- 4. Vaziri ND. Mechanisms of lead-induced hypertension and
cardiovascular disease. Am J Physiol Heart Circ Physiol 2008;
295: 454-465.
- 5. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C,
Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M. Endocan
or endothelial cell specific molecule-1 (ESM-1): a potential
novel endothelial cell marker and a new target for cancer
therapy. Biochim Biophys Acta 2006; 1765: 25-37.
- 6. Aparci M, Isilak Z, Uz O, Yalcin M, Kucuk U. Endocan and
endothelial dysfunction. Angiology 2015; 66: 488-489.
- 7. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan
levels are correlated with the presence and severity of coronary
artery disease in patients with hypertension. Genet Test Mol
Biomarkers 2015; 19:124-127.
- 8. Balta S, Demirkol S, Ozturk C, Yildirim AO, Demir M,
Celik T. The relation between endocan levels and subclinic
atherosclerosis. Clin Appl Thromb Hemost 2016; 22: 495-496.
- 9. Kundi H, Balun A, Cicekcioglu H, Karayigit O, Topcuoglu
C, Kilinckaya MF, Kiziltunc E, Cetin M, Ornek E. Admission
endocan level may be a useful predictor for in-hospital
mortality and coronary severity index in patients with STsegment elevation myocardial infarction. Angiology 2017; 68:
46-51.
- 10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E,
Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS
et al. Recommendations for chamber quantification: a report
from the American Society of Echocardiography’s Guidelines
and Standards Committee and the Chamber Quantification
Writing Group, developed in conjunction with the European
Association of Echocardiography, a branch of the European
Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-
1463.
- 11. Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T,
Tsutsumi M. Serum endocan as a novel prognostic biomarker
in patients with hepatocellular carcinoma. J Cancer 2014; 5:
221-230.
- 12. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar
E. Blood lead below 0.48 micromol/L (10 microg/dL) and
mortality among US adults. Circulation 2006; 114: 1388-1394.
- 13. Ma LN, Zhao SP, Gao M, Zhou QC, Fan P. Endothelial
dysfunction associated with left ventricular diastolic
dysfunction in patients with coronary heart disease. Int J
Cardiol 2000; 72:275-279.
- 14. Sirivarasai J, Wananukul W, Kaojarern S, Chanprasertyothin
S, Thongmung N, Ratanachaiwong W, Sura T, Sritara P.
Association between inflammatory marker, environmental
lead exposure, and glutathione S-transferase gene. Biomed Res
Int 2013; 2013: 474963.
- 15. Vaziri ND, Khan M. Interplay of reactive oxygen species and
nitric oxide in the pathogenesis of experimental lead-induced
hypertension. Clin Exper Pharmacol Physiol 2007; 34: 920-
925.
- 16. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary
endothelial control of left ventricular function in humans.
Circulation 1995; 92: 2119-2126.
- 17. Elesber AA, Redfield MM, Rihal CS, Prasad A, Lavi S, Lennon
R, Mathew V, Lerman LO, Lerman A. Coronary endothelial
dysfunction and hyperlipidemia are independently associated
with diastolic dysfunction in humans. Am Heart J 2007; 153:
1081-1087.
- 18. Munzel T, Gori T, Keaney JF Jr., Maack C, Daiber A.
Pathophysiological role of oxidative stress in systolic and
diastolic heart failure and its therapeutic implications. Eur
Heart J 2015; 36: 2555-2564.
- 19. Peller M, Ozieranski K, Balsam P, Grabowski M, Filipiak KJ,
Opolski G. Influence of beta-blockers on endothelial function:
A meta-analysis of randomized controlled trials. Cardiol J
2015; 22:708-716.
- 20. Iavicoli I, Carelli G, Stanek EJ 3rd, Castellino N, Calabrese EJ.
Below background levels of blood lead impact cytokine levels
in male and female mice. Toxicol Appl Pharmacol 2006; 210:
94-99.
- 21. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu
E, Demir M, Celik T, Turker T, Iyisoy A. Endocan—a novel
inflammatory indicator in newly diagnosed patients with
hypertension: a pilot study. Angiology 2014; 65: 773-777.
- 22. Cimen T, Efe TH, Akyel A, Sunman H, Algul E, Sahan
HF, Erden G, Ozdemir S, Alay EF, Dogan M et al. Human
endothelial cell-specific molecule-1 (endocan) and coronary
artery disease and microvascular angina. Angiology 2016; 67:
846-853.
- 23. Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu
M, Yuruyen G, Arman Y, Tukek T. Serum Endocan Level
and the Severity of Coronary Artery Disease: A Pilot Study.
Angiology 2015; 66: 727-731.
- 24. Arman Y, Akpinar TS, Kose M, Emet S, Yuruyen G, Akarsu M,
Ozcan M, Yegit O, Cakmak R, Altun O et al. Effect of glycemic
regulation on endocan levels in patients with diabetes: a
preliminary study. Angiology 2016; 67:239-244.
- 25. Qiu CR, Fu Q, Sui J, Zhang Q, Wei P, Wu Y, Zhu K, Lu Y,
Wan P. Analysis of serum endothelial cell-specific molecule
1 (endocan) level in type 2 diabetes mellitus with acute stsegment elevation myocardial infarction and its correlation: a
pilot study. Angiology 2017; 68: 74-78.
- 26. Vaziri ND, Liang K, Ding Y. Increased nitric oxide inactivation
by reactive oxygen species in lead-induced hypertension.
Kidney Int 1999; 56: 1492-1498.
- 27. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Celik T, Iyisoy
A. Endocan: a novel inflammatory indicator in cardiovascular
disease? Atherosclerosis 2015; 243: 339-343.